Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03490539 · ClinicalTrials.gov registry record
Disease-Modifying Treatments for Myasthenia Gravis
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 82
- Enrollment target
NCT03490539 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 82 participants.
The verdict
NCT03490539 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them. It is a prospective, multicenter observational cohort study of comparative effectiveness of MG treatments, with a patient-centered primary outcome measure, to guide clinicians, patients and payers regarding the choice of treatment options for this chronic and serious disease. Primary: To compare the effectiveness of azathioprine (AZT) and mycophenolate mofetil (MMF). Secondary: To compare the outcomes in patients receiving an adequate dose and duration of AZT or MMF over the 2-3 year study period, vs. patients not receiving adequate doses and duration of these agents
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Azathioprine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2021-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03490539
The ClinicalTrials.gov registry entry for NCT03490539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mycophenolate Mofetil is the first listed.
NCT03490539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03490539 about?
NCT03490539 is a clinical study titled "Disease-Modifying Treatments for Myasthenia Gravis". This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them. It is a prospective, multicenter observational cohort study of comparative effectiveness of MG treatments, with a patient-centered primary outcome mea...
What is the current status of trial NCT03490539?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2018-05-07. Estimated completion is 2021-01-31.
What interventions are being tested in trial NCT03490539?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Azathioprine (DRUG).
Who is sponsoring clinical trial NCT03490539?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.